Table IV.
Characteristics of included studies (part 4).
| Citation | Risk factors adjusted | Temporality |
|---|---|---|
| Grimes et al. (1985) | Age, race, parity; same hospital, same study period | Investigated risk of newly diagnosed SLE in women with and without ENDO hix |
| Lamb and Nichols (1986) | — | Investigated risk of ENDO in women with and without RA hix |
| Smith et al. (1993) | — | Investigated risk of ENDO in women with and without SLE/AD hix |
| Sinaii et al. (2002) | — | Prevalence study of AD (SLE, MS, RA, SS, thyroid disorder) in women with ENDO vs. general women population |
| Merlino et al. (2003) | Age, smoking status, age at last pregnancy, drug to stop lactation, age at menopause, polycystic ovary syndrome, HRT | Prospective cohort study for incident RA occurred after 1987 with ENDO exposure Ø |
| Poppe and Velkeniers (2003) | Control matched on age | Investigated risk of ENDO in women with and without having thyroid auto-immunity |
| Haga et al. (2005) | Control matched on age, region | Investigated risk of SS in women with and without ENDO hix |
| Pasoto et al. (2005) | — | Clinical manifestations/serological tests for women with ENDO vs. SLE vs. healthy controls; women diagnosed with ENDO by laparoscopy after SLE diagnosis was identified as ENDO cases |
| Petta et al. (2007) | — | Investigated risk of ENDO in women with and without thyroid disorder |
| Eaton et al. (2007) | Age, sex | Cross-sectional study of ADs prevalence (ENDO listed as an AD) |
| Matorras et al. (2007) | — | Investigated risk of SLE, SS in women with and without ENDO hix and risk of ENDO in women with and without AD hix |
| Aguiar et al. (2009) | Control from same city | Investigated risk of ENDO in women with and without CLD hix |
| Gemmill et al. (2010) | — | Prevalence study of Addison’s disease in women with ENDO hix vs. general women population |
| Stephansson et al. (2011) | Control matched on age, county, period | Prospective cohort study for incident ENDO in women with and without CLD hix Ø; excluded cases with ENDO diagnosis before CLD diagnosis |
| Nielsen et al. (2011) | Control matched on age, period | Prospective cohort study for incident SLE, SS, MS in women with and without ENDO hix vs. general women population; women diagnosed with AD before ENDO diagnosis was excluded Ø |
| Jess et al. (2012) | Control matched on age, period | Prospective cohort study for incident IBD in women with and without ENDO hix Ø |
| Santoro et al. (2014) | — | Investigated risk of ENDO in women with and without CLD hix |
| Caserta et al. (2016) | — | Investigated risk of ENDO in women with and without AD hix |
| Harris et al. (2016a) | Age at menarche, parity, menstrual cycle length, BMI, physical activity, smoking, OCP, ethnicity, infertility and analgesic use. For RA plus parity, duration of breast feeding. | Prospective cohort study for incident SLE, RA in women with and without ENDO hix Ø |
| Harris et al. (2016b) | Control matched on age, county | Investigated risk of SLE in women with and without ENDO hix; selected SLE diagnosis after ENDO diagnosis |
| Yuk et al. (2016) | Control matched on age, sampling year, sampling weight | Prevalence study of ATD in women with and without ENDO hix |
| Huang et al. (2016) | Matched controls (not specified) | Investigated risk of ENDO in women with and without rheumatoid disease hix |
| Lee et al. (2016) | Control matched on age | Clinical manifestation, prognosis, and treatment comparing women with IBD and ENDO vs. women with IBD but without ENDO |
| Brouwer et al. (2017) | — | Prevalence study of ENDO in women with RA vs. general women |
| Wu et al. (2017) | Case–control study for risk of ENDO in relation to SS hix SS | |
| de Silva et al. (2018) | Investigated risk of IBD at pregnancies in women with and without ENDO hix |
AD, autoimmune disease; ATD, autoimmune thyroid disorder; ENDO, endometriosis; OCP, oral contraceptive pill; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; RA, rheumatoid arthritis; CLD, coeliac disease; MS, multiple sclerosis; IBD, inflammatory bowel disease; HRT, hormone replacement therapy.
Ø Denotes studies that addressed disease diagnosis time during data analysis.